(-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson's disease

Zhou,Tingting; Zhu,Mengru; Liang,Zhanhua

doi:10.3892/mmr.2018.8470

(-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson's disease

Authors:
- Tingting Zhou
- Mengru Zhu
- Zhanhua Liang
View Affiliations

Affiliations: Department of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Plastic Surgery, China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: January 23, 2018 https://doi.org/10.3892/mmr.2018.8470
Pages: 4883-4888
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

(-)-Epigallocatechin-3-gallate (EGCG) is the most widely studied catechin in green tea and has been identified to regulate immune function. The objective of the present study was to explore the possible application of EGCG in the treatment of Parkinson's disease (PD) by examining its effects on the peripheral immune system in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)‑induced PD mouse model. The results demonstrated that EGCG treatment restored the movement behavior of the mice impaired by MPTP, and protected tyrosine hydroxylase‑positive cells in the substantia nigra pars compacta region from MPTP toxicity. Flow cytometric analysis indicated that the ratio of CD3+CD4+ to CD3+CD8+ T lymphocytes in the peripheral blood increased in MPTP‑treated mice following treatment with EGCG, and EGCG reduced expression of inflammatory factors tumor necrosis factor‑α and interleukin‑6 in serum. The present findings indicated that EGCG serves neuroprotective effects in an MPTP‑induced PD mice model and may exert this through modulating peripheral immune response.

View Figures

View References

1	Dauer W and Przedborski S: Parkinson's disease: Mechanisms and models. Neuron. 39:889–909. 2003. View Article : Google Scholar : PubMed/NCBI
2	Jenner P and Olanow CW: The pathogenesis of cell death in Parkinson's disease. Neurology. 66 10 Suppl 4:S24–S36. 2006. View Article : Google Scholar : PubMed/NCBI
3	Chau KY, Ching HL, Schapira AH and Cooper JM: Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: Relevance to Parkinson's disease pathogenesis. J Neurochem. 110:1005–1013. 2009. View Article : Google Scholar : PubMed/NCBI
4	Lees AJ, Hardy J and Revesz T: Parkinson's disease. Lancet. 373:2055–2066. 2009. View Article : Google Scholar : PubMed/NCBI
5	Badger JL, Cordero-Llana O, Hartfield EM and Wade-Martins R: Parkinson's disease in a dish-Using stem cells as a molecular tool. Neuropharmacology. 76:88–96. 2014. View Article : Google Scholar : PubMed/NCBI
6	Dexter DT and Jenner P: Parkinson disease: From pathology to molecular disease mechanisms. Free Radic Biol Med. 62:132–144. 2013. View Article : Google Scholar : PubMed/NCBI
7	Hernández-Romero MC, Delgado-Cortés MJ, Sarmiento M, de Pablos RM, Espinosa-Oliva AM, Argüelles S, Bández MJ, Villarán RF, Mauriño R, Santiago M, et al: Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system. Neurotoxicology. 33:347–360. 2012. View Article : Google Scholar : PubMed/NCBI
8	Chen H, O'Reilly EJ, Schwarzschild MA and Ascherio A: Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 167:90–95. 2008. View Article : Google Scholar : PubMed/NCBI
9	Amor S and Woodroofe MN: Innate and adaptive immune responses in neurodegeneration and repair. Immunology. 141:287–291. 2014. View Article : Google Scholar : PubMed/NCBI
10	Olson KE and Gendelman HE: Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Curr Opin Pharmacol. 26:87–95. 2016. View Article : Google Scholar : PubMed/NCBI
11	Levites Y, Weinreb O, Maor G, Youdim MB and Mandel S: Green tea polyphenol (−)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem. 78:1073–1082. 2001. View Article : Google Scholar : PubMed/NCBI
12	Choi JY, Park CS, Kim DJ, Cho MH, Jin BK, Pie JE and Chung WG: Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology. 23:367–374. 2002. View Article : Google Scholar : PubMed/NCBI
13	Kuo CL, Chen TS, Liou SY and Hsieh CC: Immunomodulatory effects of EGCG fraction of green tea extract in innate and adaptive immunity via T regulatory cells in murine model. Immunopharmacol Immunotoxicol. 36:364–370. 2014. View Article : Google Scholar : PubMed/NCBI
14	Yoneyama S, Kawai K, Tsuno NH, Okaji Y, Asakage M, Tsuchiya T, Yamada J, Sunami E, Osada T, Kitayama J, et al: Epigallocatechin gallate affects human dendritic cell differentiation and maturation. J Allergy Clin Immunol. 121:209–214. 2008. View Article : Google Scholar : PubMed/NCBI
15	Kuang X, Huang Y, Gu HF, Zu XY, Zou WY, Song ZB and Guo QL: Effects of intrathecal epigallocatechin gallate, an inhibitor of Toll-like receptor 4, on chronic neuropathic pain in rats. Eur J Pharmacol. 676:51–56. 2012. View Article : Google Scholar : PubMed/NCBI
16	Jackson-Lewis V and Przedborski S: Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc. 2:141–151. 2007. View Article : Google Scholar : PubMed/NCBI
17	Wei IH, Wu YC, Wen CY and Shieh JY: Green tea polyphenol (−)-epigallocatechin gallate attenuates the neuronal NADPH-d/nNOS expression in the nodose ganglion of acute hypoxic rats. Brain Res. 999:73–80. 2004. View Article : Google Scholar : PubMed/NCBI
18	Sedelis M, Schwarting RK and Huston JP: Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res. 125:109–125. 2001. View Article : Google Scholar : PubMed/NCBI
19	Stone DK, Reynolds AD, Mosley RL and Gendelman HE: Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal. 11:2151–2166. 2009. View Article : Google Scholar : PubMed/NCBI
20	McGeer PL and McGeer EG: Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci. 1035:104–116. 2004. View Article : Google Scholar : PubMed/NCBI
21	Wahner AD, Bronstein JM, Bordelon YM and Ritz B: Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology. 69:1836–1842. 2007. View Article : Google Scholar : PubMed/NCBI
22	Choi JG, Kim HG, Kim MC, Yang WM, Huh Y, Kim SY and Oh MS: Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models. J Ethnopharmacol. 134:414–421. 2011. View Article : Google Scholar : PubMed/NCBI
23	Hwang DS, Kim HG, Kwon HJ, Cho JH, Lee CH, Lee JM, Jang JB, Kim YS, Lee KS and Oh MS: Dangguijakyak-san, a medicinal herbal formula, protects dopaminergic neurons from 6-hydroxydopamine-induced neurotoxicity. J Ethnopharmacol. 133:934–939. 2011. View Article : Google Scholar : PubMed/NCBI
24	Lu C, Zhang J, Shi X, Miao S, Bi L, Zhang S, Yang Q, Zhou X, Zhang M, Xie Y, et al: Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP. Int J Biol Sci. 10:350–357. 2014. View Article : Google Scholar : PubMed/NCBI
25	Katiyar SK, Challa A, McCormick TS, Cooper KD and Mukhtar H: Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (−)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis. 20:2117–2124. 1999. View Article : Google Scholar : PubMed/NCBI
26	Goldberg NR, Haack AK, Lim NS, Janson OK and Meshul CK: Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 180:256–271. 2011. View Article : Google Scholar : PubMed/NCBI
27	Amor S, Peferoen LA, Vogel DY, Breur M, van der Valk P, Baker D and van Noort JM: Inflammation in neurodegenerative diseases-an update. Immunology. 142:151–166. 2014. View Article : Google Scholar : PubMed/NCBI
28	Bas J, Calopa M, Mestre M, Molleví DG, Cutillas B, Ambrosio S and Buendia E: Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol. 113:146–152. 2001. View Article : Google Scholar : PubMed/NCBI
29	Dinarello CA: Historical insights into cytokines. Eur J Immunol. 37 Suppl 1:S34–S45. 2007. View Article : Google Scholar : PubMed/NCBI
30	Koziorowski D, Tomasiuk R, Szlufik S and Friedman A: Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine. 60:762–766. 2012. View Article : Google Scholar : PubMed/NCBI
31	Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C and Peterson DW: Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand. 100:34–41. 1999. View Article : Google Scholar : PubMed/NCBI